Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-[alpha]2b: A Randomized Trial
| Autor: | Carlos E. Brandao-Mello, Donald M. Jensen, B. Freilich, Antonio Olveira Martin, Patrick Marcellin, Antonio Craxì, James Thommes, G. Teuber, Diethelm Messinger, Adrian M. Di Bisceglie, K. Rajender Reddy, Andreas Tietz, Pietro Andreone |
|---|---|
| Přispěvatelé: | Jensen, DM, Marcellin, P, Freilich, B, Andreone, P, Di Bisceglie, A, Brandão-Mello, CE, Reddy, KR, Craxi, A, Martin, AO, Teuber, G, Messinger, D, Thommes, JA, Tietz, A, Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A. |
| Jazyk: | němčina |
| Rok vydání: | 2009 |
| Předmět: |
Male
medicine.medical_specialty Hepatitis C virus Alpha interferon Hepacivirus Interferon alpha-2 medicine.disease_cause Antiviral Agents Gastroenterology Drug Administration Schedule Polyethylene Glycols law.invention chemistry.chemical_compound Double-Blind Method Randomized controlled trial law Pegylated interferon Internal medicine Ribavirin Internal Medicine retreatment non responder hepatitis C Humans Medicine Treatment Failure Not evaluated business.industry Interferon-alpha virus diseases General Medicine Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease Recombinant Proteins digestive system diseases Surgery chemistry Retreatment RNA Viral Drug Therapy Combination Female business Viral load medicine.drug |
| Zdroj: | Scopus-Elsevier |
| Popis: | BACKGROUND Many patients with chronic hepatitis C have not responded to therapy with pegylated interferon plus ribavirin. OBJECTIVE To evaluate use of peginterferon-alpha2a plus ribavirin to re-treat nonresponders to peginterferon-alpha2b plus ribavirin. DESIGN Randomized, parallel-group trial conducted between September 2003 and February 2007. Patients and researchers were not blinded to intervention assignment. Random assignment was centralized, computer-generated, and stratified by geographic region, hepatitis C virus (HCV) genotype, and histologic diagnosis. SETTING 106 international centers. PATIENTS 950 nonresponders to 12 or more weeks of therapy with peginterferon-alpha2b plus ribavirin. INTERVENTION Peginterferon-alpha2a, 360 microg/wk, for 12 weeks, then 180 microg/wk to complete 72 weeks (group A) or 48 weeks (group B), or peginterferon-alpha2a, 180 microg/wk for 72 weeks (group C) or 48 weeks (group D). All patients received ribavirin, 1000 or 1200 mg/d. MEASUREMENTS Sustained virologic response (SVR), defined as undetectable ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|